{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:23Z","timestamp":1792460303460,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The cardiovascular (CV) benefits of glucagon\u2010like\u2010peptide\u20101 receptor agonist (GLP\u20101 RA) therapies are not well\u2010established in women with breast cancer and type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The primary objective of this study was to compare the incidence of major adverse cardiovascular events (MACE) in women with T2D and breast cancer receiving GLP\u20101 RA therapy versus non\u2010GLP\u20101 RA diabetes medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included women with T2D, diagnosed with breast cancer at \u2265\u200940\u2009years old from December 16, 2014 to December 16, 2024 and having exposure to diabetes medications of interest (either GLP\u20101 RA or non\u2010GLP\u20101 RA) within 5\u2009years of these diagnoses. The primary end point, MACE, was a composite of myocardial infarction, ischemic stroke, coronary revascularization, cardiac arrest, or heart failure, within 5\u2009years of the index date. Propensity score matching was performed. Participants were excluded from each individual outcome analysis if they had the outcome prior to the index date. Incidence rates, risk ratio (RR), 95% confidence interval (CI), and\n                      <jats:italic>p<\/jats:italic>\n                      \u2010value were reported for each outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 19,608 patients were included in each cohort (mean age 64\u2009years). Obesity and alkylating agents were more commonly reported in the GLP\u20101 RA cohort. Semaglutide was the most prescribed GLP\u20101 RA at index (45.1%). MACE occurred in 10.6% of the GLP\u20101 RA cohort and 13.4% of the non\u2010GLP\u20101 cohort (RR 0.80, 95% CI 0.75\u20130.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Individual MACE end points, ischemic heart disease, and end\u2010stage renal disease were significantly lower in the GLP\u20101 RA\u2010treated cohort. GLP\u20101 RA use was also associated with a 61.6% relative risk reduction in all\u2010cause mortality (RR 0.38, 95% CI 0.36\u20130.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Pancreatitis incidence was similar between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.057), whereas cholelithiasis was significantly lower with GLP\u20101 RA therapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated the potential CV benefit of GLP\u20101 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70130","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:19:15Z","timestamp":1773076755000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010World Cardiovascular Outcomes of\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-675X","authenticated-orcid":false,"given":"Cyrille K.","family":"Cornelio","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-1600","authenticated-orcid":false,"given":"Kevin","family":"Cowart","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-9061","authenticated-orcid":false,"given":"Janelle","family":"Perkins","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed E.","family":"Alomar","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center &amp; Research Institute  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Pineda","family":"Gayoso","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center &amp; Research Institute  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1683-3982","authenticated-orcid":false,"given":"Aimon C.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T.","family":"Phan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-5590","authenticated-orcid":false,"given":"Raechel T.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.042"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020406"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33530"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040678"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14496"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2009.04.001"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa082"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10\u20101393"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31149\u20103"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115170"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091593"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25\u2010328\u2010OR"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S009"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.12026"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T13:13:32Z","timestamp":1780146812000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/phar.70130"],"URL":"https:\/\/doi.org\/10.1002\/phar.70130","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70130"}}